Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Dec 1;25(12):4123-4128.
doi: 10.31557/APJCP.2024.25.12.4123.

Assessment of Hematological Toxicity of Adjuvant Chemotherapy in the Complex Therapy of Breast Cancer

Valentina B Sirota  1 , Sabina Sakenovna Zhumakayeva  1 , Nailya Amirbekovna Kabildina  1 , Daria Dmitrievna Dorogan  1 , Zarina Bilyalova  2 , Sergazy M Adekenov  2
Affiliations
Multicenter Study

Assessment of Hematological Toxicity of Adjuvant Chemotherapy in the Complex Therapy of Breast Cancer

Valentina B Sirota et al. Asian Pac J Cancer Prev. .

Abstract

Within the framework of multicenter clinical studies of the original anticancer drug "Arglabin" in the complex therapy of breast cancer (BC) in an increased dose on the basis of the Regional Oncological Dispensary, Karaganda, 80 patients BC were examined and treated: 40 patients in the control group and 40 in the study group. The index of grade I anemia was higher in patients of the control group: in (15.6±6.42)% of patients with polychemotherapy (PCT) AC and in (6.9±4.7)% of patients with PCT according to the scheme AC+Arglabin (p<0.05). The inclusion of Arglabin to the AC regimen increases the rate of absence of toxicity to blood leukocytosis by 25.2% (69.0±8.6%) compared with the group of patients receiving APCT according to the AC regimen (43.8±8.8%); decrease in grade I leukopenia by 2.7 times (from 28.13±7.95% to 10.3±5.7%, p≤0.05); 2-fold decrease in grade 2 leukopenia (from 28.1±7.95% to 13.8±6.4%). The inclusion of Arglabin to the AC regimen in APCT in BC patients increases the rate of absence of toxicity to blood granulocytosis by 14.8% (67.9±8.8%) compared to the group of patients who received APCT according to the AC regimen (53.1±8.8%); a decrease in grade 2 granulocytopenia by 3.9 times (from 28.1±7.95% to 7.14±4.9%, p≤0.05). The inclusion of Arglabin to the adjuvant chemotherapy regimen eliminates the toxic effect of chemotherapy on erythrocytosis, leukocytosis and granulocytosis. No effect of arglabin on blood platelets indicators in breast cancer patients was revealed.

Keywords: Adjuvant chemotherapy; arglabin; breast cancer; toxicity of chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflict of interests.

References

    1. Almaty: Krior mh rk. 2020. Indicators of the oncological service of the republic of kazakhstan for 2019 (statistical materials) p. 230. (in russian)
    1. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, et al. Effects of screening and systemic adjuvant therapy on er-specific us breast cancer mortality. J Natl Cancer Inst. 2014;106:11. - PMC - PubMed
    1. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. The Lancet Oncology. 2010;11(1):55–65. - PMC - PubMed
    1. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, her2-positive breast cancer. N Engl J Med. 2015;372(2):134–41. - PMC - PubMed
    1. Ionova Ti, Novik Aa, Sukhonos Yua. The concept of the life quality of cancer patients. Oncology. 2000;1-2:25–27.

Publication types

MeSH terms